Disable all preview features

Health : Medical Research

Drugs for Neglected Diseases Initiative North America

Developing new drugs for patients suffering from the most neglected communicable diseases

three stars

85.56

40 Wall Street 24th Floor
New York, NY 10005
tel: (646) 616-8680   Web Site
EIN: 20-8774179

Board Leadership
Bennett Shapiro
Chair

CEO
Rachel Cohen
Regional Executive Director

  Score
(out of 100)
Rating
Overall Score & Rating 85.56 three stars
  Financial 79.98 two stars
  Accountability & Transparency 96.00 four stars
This rating was published 02/01/2018 and includes data from FY2016, the most recent 990 received at that time.

The mission of Drugs for Neglected Diseases Initiative North America (DNDi NA) is to develop new drugs, or new formulations of existing drugs, for patients suffering from the most neglected communicable diseases. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. DNDi's primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), visceral leishmaniasis (kala-azar), and Chagas disease, while considering engagement in R&D projects for other neglected diseases or development of diagnostics and/or vaccines to address unmet needs that others are unable or unwilling to address.

The mission of Drugs for Neglected Diseases Initiative North America (DNDi NA) is to develop new drugs, or new formulations of existing drugs, for patients suffering from the most neglected communicable diseases. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. DNDi's primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), visceral leishmaniasis (kala-azar), and Chagas disease, while considering engagement in R&D projects for other neglected diseases or development of diagnostics and/or vaccines to address unmet needs that others are unable or unwilling to address.

Financial

two stars

79.98

Accountability & Transparency

four stars

96.00

This rating was published 02/01/2018 and includes data from FY2016, the most recent 990 received at that time.
Overall Rating Chart
  Program Expenses
(Percent of the charity's total expenses spent on the programs
and services it delivers)
76.2%
  Administrative Expenses 5.7%
  Fundraising Expenses 17.9%
  Fundraising Efficiency $0.16
  Working Capital Ratio (years) 0.22
  Program Expenses Growth 31.8%
  Liabilities to Assets 28.7%
All data for Financial Performance Metrics calculations was provided by Drugs for Neglected Diseases Initiative North America on recent 990s filed with the IRS.
All data for Financial Performance Metrics calculations was provided by Drugs for Neglected Diseases Initiative North America on recent 990s filed with the IRS.

Highly Rated

Charity Name & State Overall Score Overall Rating
Drugs for Neglected Diseases Initiative North America (NY) 85.56 three stars
American Foundation for Surgery of the Hand (IL) 90.87 four stars
Vascular Cures (CA) 87.25 three stars
Food Allergy Research & Education (VA) 90.20 four stars
Dysautonomia Foundation (NY) 86.64 three stars

Compare These Charities (Highly Rated)

REVENUE  
Contributions  
   Contributions, Gifts & Grants $2,411,549
   Federated Campaigns $0
   Membership Dues $0
   Fundraising Events $0
   Related Organizations $0
   Government Grants $807,192
Total Contributions $3,218,741
   Program Service Revenue $0
Total Primary Revenue $3,218,741
   Other Revenue $241
TOTAL REVENUE $3,218,982
   
EXPENSES  
   Program Expenses $2,414,640
   Administrative Expenses $177,504
   Fundraising Expenses $394,582
TOTAL FUNCTIONAL EXPENSES $2,986,726
   
Payments to Affiliates $0
Excess (or Deficit) for the year $232,256
   
Net Assets $566,614

Program names and associated costs are listed for the top programs as reported on the charity's most recently filed Form 990. The top programs displayed will include the largest three programs, or those programs covering at least 60% of the charity's total expenses, whichever comes first.

Program Name Amount Spent % of Program Expenses
Grants to Research and Development $1,963,388 81.3%
Raising Public Awareness $451,252 18.7%

Ratings History

Form 990 FYE Date Published Overall Score Overall Rating
CN 2.1
2016-12 02/01/2018 85.56 three stars
2015-12 02/01/2017 75.82 two stars
2015-12 12/01/2016 73.74 two stars
2014-12 06/01/2016 79.38 two stars
 
CN 2.0
2014-12 02/01/2016 70.67 two stars

The data displayed on this tab is provided by the IRS in the form of Publication 78 and the Business Master File (BMF).

EIN 20-8774179
Name in IRS Master File DRUGS FOR NEGLECTED DISEASESINITIATIVE NORTH AMERICA INC
NTEE Code E05
NTEE Classification Research Institutes and/or Public Policy Analysis
NTEE Type Health - General and Rehabilitative
Classification Charitable Organization
Subsection 501(c)(3)  (View the list of codes)
Activities
Foundation Status Organization which receives a substantial part of its support from a governmental unit or the general public   170(b)(1)(A)(vi)
Deductibility Contributions are deductible
Affiliation Independent - the organization is an independent organization or an independent auxiliary (i.e., not affiliated with a National, Regional, or Geographic grouping of organizations).
Group Name [Not Applicable]
Ruling Date November, 2007
Filing Requirement 990 (all other) or 990EZ return
Fiscal Year End December
IRS Forms 990
(provided courtesy of Foundation Center)
(Log In or Register Now to View Forms 990!)
  • December, 2016
  • December, 2015
  • December, 2014
  • December, 2013
  • December, 2012

The data displayed in this profile is provided by the IRS for free in the form of Publication 78 and the Business Master File (BMF).

Compensation % of Expenses Paid to Title
$154,141 5.16% Rachel Cohen Executive Director

Highly Rated

Charity Name & State Overall Score Overall Rating
Drugs for Neglected Diseases Initiative North America (NY) 85.56 three stars
Foundation for Prader-Willi Research (CA) 91.29 four stars
International Rett Syndrome Foundation (OH) 89.39 three stars
Citizens United for Research in Epilepsy (IL) 94.69 four stars
Monell Chemical Senses Center (PA) 86.45 three stars

Compare These Charities (Highly Rated)

This charity has an official representative registered with Charity Navigator.

Charity Contact Info

Drugs for Neglected Diseases Initiative North America
40 Wall Street
24th Floor
New York, NY 10005
tel: (646) 616-8680
EIN: 20-8774179

Visit Web Site

Board Leadership

Bennett Shapiro
Chair

CEO

Rachel Cohen
Regional Executive Director

Join Our Mailing List

Join over 400,000 other informed givers and get updates on charity ratings, new features, hot topics, and tips for donating.